At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,494 enrolled
Drug / intervention
norelgestromin + ethinyl estradiol; triphasil.drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Oct 12, 2005·Updated Jun 8, 2011
In Brief
A Phase 3 clinical trial evaluating norelgestromin + ethinyl estradiol; triphasil. for Contraception and Female Contraception. Completed, enrolled 1,494 participants.
Detailed Summary
The purpose of the study was to compare the contraceptive efficacy and safety of the transdermal patch to Triphasil.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsContraception, Female Contraception
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 1997
Study CompletionMar 1999
First PostedOct 2005
TodayJul 2026
First PostedOct 12, 2005
Enrollment StartJan 1, 1997
Study CompletionMar 1, 1999
TodayJul 2, 2026
Posted 20.7 years ago
Interventions
norelgestromin + ethinyl estradiol; triphasil.drug